ArticleBMC cardiovascular disorders2026
Association between triglyceride glucose-body mass index and all-cause mortality in critically ill patients with atherosclerotic cardiovascular diseases: a retrospective cohort study using the MIMIC-IV database.
Article in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAtherosclerotic cardiovascular disease (ASCVD) remains the leading cause of cardiovascular mortality worldwide, with insulin resistance recognized as a key pathophysiological driver. While the triglyceride glucose-body mass index (TyG-BMI) has emerged as a promising insulin resistance marker, its prognostic value for ASCVD mortality outcomes requires further elucidation.
methodsWe conducted a retrospective cohort study of 1,637 critically ill ASCVD patients (median age 68.3 years) from the MIMIC-IV database. The primary endpoints were 30-day and 1-year mortality, with secondary assessments of 90-day and 180-day mortality. Comprehensive statistical analyses included multivariable Cox regression, restricted cubic splines (RCSs) for nonlinearity assessment, and Kaplan-Meier survival analysis.
resultsAfter full adjustment for potential confounders, elevated TyG-BMI showed significant inverse associations with both 30-day (HR 0.11, 95% CI 0.06-0.19) and 1-year mortality (HR 0.13, 95% CI 0.08-0.20). RCS analysis revealed a characteristic L-shaped dose-response relationship (nonlinear P < 0.001), while Kaplan-Meier curves demonstrated progressively improved survival across TyG-BMI quartiles (log-rank P < 0.001).
conclusionThis study revealed that the TyG-BMI is an independent predictor of mortality in critically ill ASCVD patients, with a distinct nonlinear protective effect. These findings support the potential clinical utility of the TyG-BMI for risk stratification in this high-risk population.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.